Amarin updates AMR101 timeline as cash reserves fall
This article was originally published in Scrip
Executive Summary
Amarin's Phase III trials of its lead product AMR101 (ethyl eicosapentaenoic acid) for elevated triglyceride levels are progressing ahead of schedule, the company reported in its first-quarter results.